Daily Watchlist . March 24, 2026

Broad selling pressure across small cap biotech today. Nine names hitting 52-week lows against two hitting highs. Here's the board.

New 52-Week Lows

BBOT $8.60. Tier 3 Miami list name. Surgical robotics/bioprinting. Grinding lower.

MNKD $2.39. Tier 1 Miami pick. MannKind, the Afrezza (inhaled insulin) company. This one hurts. Sub-$2.50 on a name with a commercial product and the Tyvaso DPI partnership with United Therapeutics. Worth watching for a bounce setup but the trend is ugly.

ADMA $13.57. ADMA Biologics, specialty plasma-derived biologics. This was a $30+ stock last year. Commercial-stage company with real revenue, getting dragged down with the sector.

NSRX $2.28. Neurosurge Therapeutics. Micro cap, thin coverage. Not in our universe.

ENTX $0.98. Tier 3 Miami name. Entera Bio just went sub-dollar. We covered this one yesterday, the oral large molecule delivery platform with EB613 heading into Phase 3 for osteoporosis. Former Pfizer exec as Chairman, board buying stock. The thesis is intact but the tape doesn't care right now.

ABT $104.10. Abbott Labs. This is a mega cap hitting 52-week lows. When a $180B healthcare blue chip is printing new lows, that tells you something about the broader risk-off environment. Not our lane but the signal matters for sentiment.

CERT $6.02. Certara, the biosimulation and regulatory science company. Model-informed drug development. Not a direct M&A play but a picks-and-shovels name for pharma R&D.

BCYC $4.25. Bicycle Therapeutics. Bicycle toxin conjugates for cancer. Had a lot of hype, steadily deflating. Phase 1/2 stage.

INMB $1.15. INmune Bio. Neuroinflammation focus, XPro1595 for Alzheimer's. Sub-$1.50 micro cap territory now.

New 52-Week Highs

CLDX $34.52. Celldex Therapeutics. Bucking the trend hard. Their anti-KIT antibody barzolvolimab for chronic spontaneous urticaria is the driver. One of the few mid-cap biotechs making new highs in this tape, which tells you the market believes in the data.

ETON $23.90. Tier 3 Miami name. Eton Pharmaceuticals, specialty pharma focused on rare disease and hospital products. Revenue-generating, profitable, and grinding higher while everything else bleeds. The anti-biotech biotech.

The Read

When ABT and ADMA, two commercial-stage names with real revenue, are hitting 52-week lows alongside pre-revenue micro caps, it's not stock-specific. It's sector-wide risk off. CLDX and ETON are the exceptions, and exceptions in a down tape tell you where the conviction is.